Mild ovarian stimulation with clomiphene citrate launch is a realistic option for in vitro fertilization

Mild stimulation using clomiphene citrate can be considered a realistic option to give patients with a good prognosis an excellent probability of pregnancy in a very short time period.

Like Comment


Anna Pia Ferraretti, Ph.D., Luca Gianaroli, M.D., Maria Cristina Magli, M.Sc., Paul Devroey, Ph.D.

Volume 104, Issue 2, Pages 333-338



To validate the use of clomiphene citrate in IVF when mild stimulation approaches are chosen to reduce patient discomfort, risk, and cost.


Prospective cohort study.


Private IVF clinic.


A total of 163 patients undergoing IVF and with a good prognosis (defined as ≤38 years old with normal ovarian reserve and normovulatory cycles, body mass index


Mild stimulation using a fixed protocol of clomiphene citrate (100 mg/d from cycle days 3 to 7) in combination with low doses of gonadotropins (150 IU of recombinant FSH on cycle days 5, 7, and 9) and GnRH antagonist.

Main Outcome Measure(s):

The cumulative delivery rate per patient after three fresh and/or frozen embryo transfers and time to pregnancy.


No dropouts were observed. The cumulative delivery rate was 70%, and the mean time to pregnancy was 2.4 months.


Mild stimulation using clomiphene citrate in combination with low doses of gonadotropins can be considered a realistic option for good-prognosis patients undergoing IVF.

Read the full text at:

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.